Navigation Links
NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
Date:10/6/2008

nd (FEV1), a standard measure of lung function, were observed with both the 50 and 100microg doses of NVA237. Early post-dose spirometry data suggested a more rapid onset of action than tiotropium. During the study, NVA237 was well tolerated with a good overall safety profile.

The other study evaluated the safety and tolerability of NVA237 (100 and 200microg once-daily) in 250 patients during 28 days of treatment. In this study, both doses were safe and well tolerated, with no clinically significant changes seen in vital signs or on other cardiac monitoring. NVA237 provided sustained 24-hour bronchodilation over the study period. The authors concluded that NVA237 should be further evaluated for the treatment of COPD.

The results of the latest studies are consistent with previous clinical studies with NVA237 which demonstrated a potentially faster onset of action than tiotropium (five minutes versus 20-30 minutes) and a good overall safety and tolerability profile.

Mr Shinichi Tamura, President & CEO of Sosei, said: "I am pleased that these two trials have further confirmed the clinical profile of NVA237 in terms of low side effects and fast onset of action and that the drug has been deemed worthy of further study."

Dr Chris Blackwell, Chief Executive of Vectura commented: "On the back of these encouraging results, we now look forward to the continued progress of NVA237, and the combination therapy, QVA149."

Notes for Editors:

About the NVA237 and QVA149 licence agreement with Novartis

Sosei and Vectura Group plc concluded a global development and commercialisation agreement with Novartis in April 2005 for their collaborative product NVA237. Novartis is responsible for developing and commercializing NVA237 both as a monotherapy and in combination with indacaterol, its once daily, long-acting beta-2 agonist, as QVA149.

Under the terms of the agreement, Sosei and Vectura to date have each received $15 million and
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
2. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
3. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
4. Pharmaleads Lead Candidate for Pain, PL37, Enters Phase I
5. Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
8. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
9. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
10. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
11. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)...  Lakeland Industries, Inc. (NASDAQ: LAKE ... clothing for industry, municipalities, healthcare and first responders ... announced that the Company accepted a commitment letter ... subject to certain terms and conditions and is ... assurances can be given that this transaction or ...
(Date:5/21/2013)... 21 de mayo de 2013 La junta ... filiales incluyen OMNIlife science®, Inc., Enztec, Ltd. y Praxim, ... su junta. Guy Mayer, un ejecutivo ortopédico experimentado, será ... David Johnson , un experto refutado en ... Antes de unirse a OSI como presidente de ...
(Date:5/21/2013)... CINCINNATI , May 21, 2013  LCA-Vision Inc. (NASDAQ: ... correction services under the Lasik Plus ® brand, announces that ... to one-year terms at today,s annual meeting of stockholders.  These ... , co-founder and President of Bahl & Gaynor Investment Counsel ... with BSC Ventures , Edgar F. Heizer ...
Breaking Medicine Technology:Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 2Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 3Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 4Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 5Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 6Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 7Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 8Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 9Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 10Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 11Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 12Lakeland Industries, Inc. Reports Fiscal 2013 Fourth Quarter and Full Year Financial Results 13Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 3LCA-Vision Reports on Annual Meeting of Stockholders 2LCA-Vision Reports on Annual Meeting of Stockholders 3LCA-Vision Reports on Annual Meeting of Stockholders 4
... 4Q07/1Q08, DALLAS, Aug. 20 Access Pharmaceuticals, ... on the clinical,development plan of ProLindac, its novel ... human clinical trials to be initiated in,late 2007/ ... ovarian,cancer patients, designed to optimize single agent dosing ...
... in the journal Blood found 92 percent reduction in ... ... Patients with a rare,blood disorder called PNH experienced a ... following treatment,with Soliris(TM) (eculizumab), according to an analysis of clinical ...
Cached Medicine Technology:Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac 2Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac 3Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac 4PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 2PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 3PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 4PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 5PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 6PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 7PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 8
(Date:5/22/2013)... adherence to appropriate medication therapy has been shown to ... 125,000 deaths in the U.S. every year are attributed ... estimated that between 33% and 69% of all medication-related ... a reality that costs the American health-care system approximately ... degree of medication non-adherence — and the consequences therefrom ...
(Date:5/22/2013)... Those who have already gone through a lap ... hardest work is yet to come. As of April 24, ... have special health needs that should be addressed in nutrition ... Surgery” abclocal.go.com/kabc/story?section=news/food_coach&id=9078455). Bariatric surgeon Dr. Madan offers four tips to ... can be lost and kept off. , First, lap ...
(Date:5/22/2013)... SAN DIEGO, CA (PRWEB) May 22, 2013 ... active lifestyle media and publishing company released today ... The 10 healthiest business hotels received the company’s ... traveler feedback, and anonymous personal tours by the ... multi-sport options (e.g., lap pool, sport court, etc.), ...
(Date:5/21/2013)... (PRWEB) May 22, 2013 The University ... teaming up with HEALTHY DINING to help Coloradans make ... , The new program is called HEALTHY DINING IN ... locations are already participating in Colorado. Restaurants will offer ... and adults emphasizing lean protein, vegetables, fruits, whole grains ...
(Date:5/21/2013)... Swimsuit season is almost here. The "Get Ready ... begun with a 35% discount. , Cellulite forms mainly in ... the dreaded cellulite even if they are in shape. ... have been stored as toxic lymph and smashed together, giving ... specific program that works to dissolve the toxins and fatty ...
Breaking Medicine News(10 mins):Health News:Patient Prompt® Announces New Drug Adherence Program to Assist in Prescribed Medication Compliance 2Health News:The Lap Band Center: Dr. Atul Madan Offers Five Tips for Ongoing Weight Loss for Lap Band Patients 2Health News:The Lap Band Center: Dr. Atul Madan Offers Five Tips for Ongoing Weight Loss for Lap Band Patients 3Health News:2013: The 10 Healthiest Business Hotels in the U.S. 2Health News:Colorado Takes a Huge Step toward Transforming the Family Dining Experience 2Health News:Colorado Takes a Huge Step toward Transforming the Family Dining Experience 3Health News:Diminish Cellulite for Swimsuit Season; Sublime Beauty Introduces Cellulite Whisperer® Products in the "Get Ready for Summer Sale" 2
... could offer clues to effects of aging, experts say ... that plays an important role in coordinating people,s circadian ... , The circadian clock governs daily cycles of ... University and the Washington University School of Medicine said ...
... ,Celebrating case reports, the stories in health care, will be ... 15 May this year, and will bring together leading doctors ... the Editors of Cases Network,s journals Richard Smith (the ... University, Australia). , Richard Smith said of Cases Network,s goal, ...
... Annual American Academy of Dermatology MeetingCRANFORD, N.J., March 19 ... Lipocream(R) (hydrocortisone butyrate 0.1%) the leading mid-potency corticosteroid ... recently launched Locoid(R) Lotion . ... Dermatology (AAD) meeting in San Francisco, ...
... The "Help is Here Express" bus tour will be ... various cities throughout the state in order to help ... provide prescription medicines for free or nearly free. With ... months, and having passed the national unemployment rate (7.6 ...
... Pa., March 19 eHealth specialist InterComponentWare (ICW) has ... at the IHE North American Connectathon, the only large-scale ... the past three years the interoperability of ICW,s Master ... conformant. The interoperability of the ICW MPI succeeded ...
... 19 VNUS Medical Technologies, Inc. (Nasdaq: VNUS ... invasive treatment of venous reflux disease, today announced its plans ... Growth Institutional Investor Forum, to be held March 24 - ... City. The management speaker will be Peter Osborne, Chief ...
Cached Medicine News:Health News:Internal Clock and Metabolism May Be Linked 2Health News:Triax Pharmaceuticals, Providers of the No. 1 Prescribed Mid-Potency Corticosteroid Brand, Introduce a New Size of Locoid Lotion 0.1% 2Health News:Partnership for Prescription Assistance Prepared to Help Georgia Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Georgia Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Georgia Workers Hurt by Recession 4Health News:ICW Master Patient Index Passes HITSP Certification and IHE Tests 2
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
... offered as 1-piece or modular, in regular ... may be customized with handles of choice ... and flush ports. Many standard patterns are ... affect delivery times. , Please Note: ...
... products are offered as 1-piece or modular, ... modular instruments may be customized with handles ... ratchets, insulation and flush ports. Many standard ... specifications may affect delivery times. , ...
... Featured Products are kept ... and are offered as ... regular or extra long ... with insulation, flush ports, ...
Medicine Products: